MetaCap

AnaptysBio (ANAB) vs uniQure N.V. (QURE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AnaptysBio (ANAB) has outperformed uniQure N.V. (QURE) over the past year, gaining 76.6% versus a loss of 30.4%. Over five years, ANAB leads with a +124.8% price change compared with -32.9% for QURE. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.

AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -1236.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANAB+76.58%QURE-30.42%
+176%+48%-79%
Nov 21, 20251 yearNov 20, 2026
ANAB+127.09%QURE-34.72%
+254%+75%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANAB versus QURE key metrics
MetricANABQURE
Share price$46.63$19.35
Market cap$1.39B$1.36B
1-day change-1.62%-4.35%
YTD return+44.28%-19.14%
1-year return+76.58%-30.42%
5-year return+124.76%-32.86%
P/E ratio (TTM)7.15—
Forward P/E8.66—
EPS (TTM)$6.52$-3.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$234.60M$16.10M
Revenue growth (YoY)+157.01%-40.64%
Net income (latest FY)$-13.23M$-198.97M
Gross margin—89.53%
Operating margin96.72%-1151.38%
Net margin-5.64%-1236.00%
52-week high$72.36$51.72
52-week low$26.01$8.73
Distance from 52-week high-35.56%-62.59%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+87.11%+207.03%
Average volume496.92K2.26M
Shares outstanding29.73M70.14M
Employees—221
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANAB has outperformed QURE by 107.0 percentage points over the past year.
  • AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
  • AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs -40.64%).

About AnaptysBio

ANAB stock →

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations

About uniQure N.V.

QURE stock →

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees

ANAB vs QURE FAQ

Which is bigger, AnaptysBio or uniQure N.V.?

AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.36B for uniQure N.V. (QURE).

Which stock has performed better over the past year, ANAB or QURE?

ANAB returned +76.58% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.

Are AnaptysBio and uniQure N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons